Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy JPMorgan Chase & Co.

Regeneron Pharmaceuticals Inc.
Start price
€974.20
17.06.24 / 50%
Target price
€1,072.3
17.06.25
Performance (%)
-54.45%
End price
€443.70
18.06.25
Summary
This prediction ended on 18.06.25 with a price of €443.70. The BUY prediction by JPMorgan_Chase___Co_ for Regeneron Pharmaceuticals Inc. performed very badly with a performance of -54.45%. JPMorgan_Chase___Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. A total of €1.72 was paid as dividends for this prediction. JPMorgan_Chase___Co_ has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m 1y
Regeneron Pharmaceuticals Inc. 6.200% 6.200% -4.374%
iShares Core DAX® 1.085% -0.846% 12.464%
iShares Nasdaq 100 -1.665% -3.306% 1.502%
iShares Nikkei 225® 3.863% 6.308% 22.272%
iShares S&P 500 0.111% -1.337% 1.101%

Comments by JPMorgan_Chase___Co_ for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) -54.45%
Target price 1072.260
Change
Ends at 17.06.25

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at JPMorgan Chase & Co. from $1,050.00 to $1,150.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat

JPMorgan Chase & Co. 
0
Report Share
17.06.24
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) -54.45%
Target price 1072.260
Change
Ends at 17.06.25

Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten

JPMorgan Chase & Co. 
0
Report Share
18.06.25

Current prediction by JPMorgan_Chase___Co_ for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€586.00
31.03.25
€922.40
31.03.26
13.86%
06.02.26

JPMorgan Chase & Co. 
31.03.25 50%

Stopped prediction by JPMorgan_Chase___Co_ for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€639.20
02.02.26
€800.09
02.02.27
3.97%
06.02.26

JPMorgan Chase & Co. 
02.02.26 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€444.50
09.06.25
€700.56
09.06.26
49.91%
06.02.26

JPMorgan Chase & Co. 
09.06.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€872.60
24.10.24
€1,064.9
24.10.25
-42.87%
25.10.25

JPMorgan Chase & Co. 
24.10.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€990.00
02.08.24
€1,099.6
02.08.25
-51.29%
03.08.25

JPMorgan Chase & Co. 
02.08.24 50%